Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aqua Bio Technology Capital/Financing Update 2024

Feb 12, 2024

3535_rns_2024-02-12_27882130-a356-49a9-89e6-11a3057c7c74.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

AQUA BIO TECHNOLOGY ASA - RESULT OF SUBSEQUENT OFFERING

12.2.2024 09:06:24 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the "Company" or "ABT") on 5 February 2024 regarding the key terms for a subsequent offering of up to NOK 5,000,000 through issuance of up to 1,000,000 new shares ("Offer Shares") in the Company at a subscription price of NOK 5 per share (the "Subsequent Offering").

In the Subsequent Offering, the shareholders of the Company as of 30 January 2024 (as registered in the VPS on 1 February 2024), except: (i) shareholders that subscribed for shares in the private placement placed on 30 January 2024, and (ii) shareholders who are resident in a jurisdiction where such offering would be unlawful, or would require any prospectus filing, registration or similar action (the "Eligible Shareholders"), received subscription rights giving preferential rights to subscribe for and be allocated Offer Shares in the Subsequent Offering. In addition, certain groups of investors, as described in the stock exchange notice dated 5 February 2024 were given a secondary right to subscribe for Offer Shares not subscribed for by the Eligible Shareholders.

The application period in the Subsequent Offering ended on 9 February 2024 at 16.30 CEST. At the end of the application period, the Company had received applications corresponding to subscription of 780,142 Offer Shares.

The Company's board of directors (the "Board") has now allocated shares in the Subsequent Offering, which implies that the Company shall issue 780,142 new shares related to the Subsequent Offering. Allocation letters, regarding the number of shares allocated and the subscription amount to be paid, will be distributed to the subscribers shortly.

Completion of the Subsequent Offering is, among other things, subject to the registration of the share capital increase pertaining to the Subsequent Offering in the Norwegian Register of Business Enterprises.

For further information, please contact Håvard Lindstrøm, CEO, telephone +47 9413 2288.

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing

natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on Euronext Expand.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Disclosure regulation

This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.

Contacts

Håvard Lindstrøm, 004794132288, [email protected]

About Aqua Bio Technology ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on Euronext Expand.

Attachments

Download announcement as PDF.pdf